Andrew Alliance and Sartorius collaborate to provide software-connected pipettes for life science research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Andrew Alliance and Sartorius have launched the Andrew Alliance Pipette+ system, which uniquely provides both full traceability and improved repeatability in manual pipetting for life science laboratories. Andrew Alliance, the robotics company with an innovative approach to liquid handling that is improving repeatability of conventional laboratory pipettes, and the Life Science company Sartorius, are collaborating to bring this intelligent pipetting solution to market.
As much as half of all research funding in life sciences is used to repeat experiments, showing that lack of reproducibility in research is an ongoing challenge in the biopharmaceutical industry. A major cause of irreproducibility has been incorrect execution in liquid handling workflows. This collaboration between Andrew Alliance and Sartorius reflects both companies’ strategic investment in designing innovative pipetting solutions to improve reproducibility and simplify the complex and time-consuming workflows.
The Andrew Alliance Pipette+ system comprises several components that communicate with one another: electronic single and multichannel pipettes, an intelligent stand, and novel cloud-based software. Andrew Alliance co-developed the Pipette+ system with Sartorius, who is manufacturing the pipette hardware. The hardware is based on Sartorius’s Picus range of award-winning, ergonomic electronic pipettes. Using current-day Internet of Things (IoT) solutions, the pipettes communicate wirelessly with the stand by Bluetooth, and the computerized charging stand communicates with Cloud servers by either Wi-Fi or Ethernet. The pipette transmits data to the stand, such as possible errors, operator identity, and step-by-step actions taken by the operator, ensuring full traceability and improved repeatability.
The software system uses Andrew Alliance’s free, browser-based intelligent software environment, OneLab. This software allows intuitive protocol design and simplified protocol execution. For instance, the software can indicate which pipette is to be used at each step in an experiment, preset the required pipetting parameters, and eject tips at the appropriate time. Thus, users can complete protocols in a few clicks. The Andrew Alliance Pipette+ system, therefore, combines the best-in-class pipetting performance, and excellent ergonomics Sartorius’ pipettes are known for, with intelligent software.
“We worked together with Andrew Alliance to provide the scientific community with a next-generation solution for manual pipetting. We’ve been at the forefront of the electronic pipette revolution with our Picus pipette and are now connecting the world of pipetting to the world of computing. This represents a quantitative leap in the performance of electronic pipettes over that of mechanical devices,” says Venkat Rao, Head Business Management, EMEA Life Science Research at Sartorius.
“Life science researchers should be confident that their often highly limited biological samples, costly reagents and time, are focused on progressing valuable research rather than unnecessarily repeating experiments,” said Piero Zucchelli, CEO and co-founder of Andrew Alliance. “Andrew Alliance and Sartorius, the market leader in electronic pipettes, are addressing the manual liquid handling repeatability problem head on.”
Enabled by this collaboration, Andrew Alliance has launched a larger family of collaborative products serving the life-science research market at the recent Society for Laboratory Automation and Screening Trade Show in Washington DC, at which it won a New Product Award for Pipette+.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.